Analyses of NRG Oncology/RTOG 9802 Suggests Both IDH-mutant WHO-defined Molecular Subgroups of High-risk Low-Grade Gliomas May Benefit from the Addition of PCV Chemotherapy to Radiotherapy

Analyses of NRG Oncology/RTOG 9802 Suggests Both IDH-mutant WHO-defined Molecular Subgroups of High-risk Low-Grade Gliomas May Benefit from the Addition of PCV Chemotherapy to Radiotherapy

CHICAGO, IL– A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment. This data was presented during a “Best of ASCO” oral presentation in the Central Nervous Systems Tumors Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Bell Caption

NRG-RTOG 9802 was a phase III Trial that assessed patients with high-risk low-grade gliomas (defined as patients at least 40 years old or who have had incomplete tumor removal) that were treated with radiotherapy (RT) with or without combination chemotherapy treatment including the drugs procarbazine, lomustine, and vincristine (PCV chemotherapy) after the patients received a biopsy or surgical resection. This analysis studied a subset of the specimens from which tissue was available for molecular profiling.

“This is the first phase III trial to evaluate the predictive value of WHO subgroups in low-grade gliomas using long-term overall survival data with the current standard of care. The results support the notions that there are benefits of PCV therapy to RT for both IDHmut-noncodel and IDHmut-codel subgroups; whereas, high-risk low-grade glioma patients with IDHwt tumors did not demonstrate any benefit from this treatment.,” stated Erica H. Bell, PhD, Associate Professor of the Department of Radiation Oncology at The Ohio State University and the first author for this NRG-RTOG 9802 abstract.

One hundred and six specimens of the 251 eligible patients from the trial could be analyzed as they had sufficient tissue and quality DNA for profiling. Of these specimens, 41% were categorized as IDHmut-noncodel, 35% were IDHmut-codel, and 24% were IDHwt. No statistically significant differences between progression-free survival (PFS) and overall survival (OS) was observed with the addition of PCV chemotherapy in the IDHwt subgroup; however, both IDH-mutant subgroups were significantly correlated with longer PFS (IDHmut/non-co-deleted, p=0.003; IDHmut/co-deleted; p<0.001) and OS (IDHmut/non-co-deleted; p=0.013; IDHmut/co-deleted; p=0.029) in the RT plus PCV arm.

Chakravarti Caption

“This study demonstrates the importance of incorporating the new WHO sub-groups into the clinical routine as it enhances the prognostic and now predictive clarification of patients with low-grade glioma, provides further insight into resistance to radiation and PCV, and guides clinical decision-making,” stated Arnab Chakravarti, MD, the senior author of the secondary analysis and Chair of Radiation Oncology at The Ohio State University Comprehensive Cancer Center -Arthur G. James Cancer Hospital.

This project was supported by The National Cancer Institute grants U10CA180868, U10CA180822, and U24CA196067, R01CA108633 (to AC), R01CA169368 (to AC), RC2CA148190 (to AC), and U10CA180850-01 (to AC), Brain Tumor Funders Collaborative Grant (to AC), and The Ohio State University CCC (to AC).


Bell EH, Won M, Fleming JL, Becker AP, McElroy J, Shaw EG, Mehta MP, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Chakravarti A. Updated Predictive Analysis of the WHO-defined Molecular Subgroups of Low-grade Gliomas within the High-risk Treatment Arms of NRG Oncology/RTOG 9802. Abstract presented at the annual meeting of the American Society of Clinical Oncology (ASCO). Chicago, IL.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

Copyright 2019 by NRG Oncology